Global Breast Cancer Liquid Biopsy Market – Industry Trends and Forecast to 2027

  • Medical Devices
  • Upcoming Report
  • Dec 2019
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Breast Cancer Liquid Biopsy Market By Product (Consumables, Kits), Circulating Biomarkers (EVs, cfDNA, ctRNA, CTCs, cfRNA, Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa), Industry Trends and  Forecast to 2027

Market Analysis and Insights: Global Breast Cancer Liquid Biopsy Market

Breast cancer liquid biopsy market is expected to account to USD 1,212.02 million by 2027 expanding at a rate of 23.09% in the forecast period of 2020 to 2027. The market will witness rapid surge of market cap amid high incidence rate of cancer and increased expenditure from various authorities and market players on the R&D activities for advancing liquid biopsy technology.

Breast cancer liquid biopsy is the investigation or detection of tumor cells in the blood sample extracted from the target cancerous site. The liquid blood sample is tested for cancerous cells or biomarkers circulating in the blood. This biopsy method helps identify the cancerous biomarkers at an early stage to help in better treatments and health care services.

Patients and physicians are enhancing their preferences for different forms of non-invasive healthcare services, whether those are treatments or diagnosis. This trend will rapidly result in market expansion of breast cancer liquid biopsy market in the forecasted period of 2020 to 2027. With the implementation of liquid biopsy, the adoption and availability of personalized medicine is highly convenient and the increasing trend of developing personalized therapeutics is expected to drive the market growth.

Concerns in relation to clinical benefits associated with this form of diagnosis for cancer is acting as a major restraint for breast cancer liquid biopsy market.

This breast cancer liquid biopsy market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Breast Cancer Liquid Biopsy Market Scope and Market Size

Breast cancer liquid biopsy market is segmented on the basis of product, circulating biomarkers and end users. Each individual segment’s growth is analysed and these insights are subsequently considered before providing you with the market overview which can help you in understanding and identification of your core applications in the broad market.

On the basis of product, breast cancer liquid biopsy market has been segmented into consumables and kits.

Breast cancer liquid biopsy market has been segmented on the basis of circulating biomarkers into extracellular vesicles (EVs), cell-free DNA (cfDNA), ctRNA, circulating tumor cells (CTCs), cfRNA and others. Others consist of cell-free protein biomarkers.

Based on end users, breast cancer liquid biopsy market has been segmented into laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories and pathology laboratories.

Breast Cancer Liquid Biopsy Market Country Level Analysis

Breast cancer liquid biopsy market is analysed and market size information is provided by country, product, circulating biomarkers and end users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa as a part of Middle East & Africa, Brazil, Argentina and Rest of South America as part of South America.

North America and Asia-Pacific will dominate the breast cancer liquid biopsy market in terms of market share and highest growth in the forecasted period of 2020 to 2027 respectively. North America’s dominant market share is caused by the preference of the region to utilize various advanced diagnostic technologies amid availability of advanced healthcare infrastructure. Asia-Pacific will grow with the highest growth rate as the focus of authorities on reducing the burden of healthcare diseases by implementing advanced technologies along with the significant rise of breast cancer prevalence in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Breast cancer liquid biopsy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for breast cancer liquid biopsy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the breast cancer liquid biopsy market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Breast Cancer Liquid Biopsy Market Share Analysis

Breast cancer liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to breast cancer liquid biopsy market.

The major players covered in the report are QIAGEN, GUARDANT HEALTH, INC, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Menarini Silicon Biosystems, Thermo Fisher Scientific Inc., Biocept, Inc., Bio-Rad Laboratories, Inc., RainDance Technologies, Inc., Fluxion Biosciences, Inc., Cynvenio Biosystems, Inc., FOUNDATION MEDICINE, INC., Sysmex Inostics, Exosome Diagnostics, Illumina, Inc. among other players domestic and global. Market Share data is available for Global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

In September 2019, Sysmex Inostics announced the launch of “SafeSEQ” liquid biopsy panels for breast and head & neck cancer, along with the availability of the “SafeSEQ Rapid Custom Development” program designed for identification and analysis of circulating tumor DNA. The test has been optimized to offer highest levels of accuracy, and sensitivity in different biopsy processes.

In May 2019, QIAGEN announced the availability of “therascreen PIK3CA RGQ PCR Kit” since receiving the U.S. FDA approval for companion diagnostic helping identify breast cancer patients that can be treated with “PIQRAY”, with the therapy being commercialized by Novartis. The kit is the first approved by the U.S. FDA for helping base different treatment decisions with the help of plasma specimens in liquid biopsy.

Customization Available : Global Breast Cancer Liquid Biopsy Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
BUY NOW ADD TO CART
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19